Nicola Bertazza Partigiani1*
Rachele Spagnol1Laura Di Michele1Micaela Santini1Benedetta Grotto1Alex Sartori1
Elita Zamperetti1
Margherita Nosadini2
Davide Meneghesso1- 1Paediatric Nephrology Unit, Department of Womens's and Children's Health, University Hospital of Padua, Padua, Italy
- 2Paediatric Neurology and Neurophysiology Unit, Department of Womens's and Children's Health, University Hospital of Padua, Padua, Italy
Hypertensive emergency is a life-threatening condition associated with severe hypertension and organ damage, such as neurological, renal or cardiac dysfunction. The most recent guidelines on pediatric hypertension, the 2016 European guidelines and the 2017 American guidelines, provide recommendations on the management of hypertensive emergencies, however in pediatric age robust literature is lacking and the available evidence often derives from studies conducted in adults. We reviewed PubMed and Cochrane Library from January 2017 to July 2021, using the following search terms: “hypertension” AND “treatment” AND (“emergency” OR “urgency”) to identify the studies. Five studies were analyzed, according to our including criteria. According to the articles reviewed in this work, beta-blockers seem to be safe and effective in hypertensive crises, more than sodium nitroprusside, although limited data are available. Indeed, calcium-channel blockers seem to be effective and safe, in particular the use of clevidipine during the neonatal age, although limited studies are available. However, further studies should be warranted to define a univocal approach to pediatric hypertensive emergencies.
Background
A hypertensive crisis is defined as an acute severe elevation in blood pressure (BP). There is not an absolute threshold to define severe hypertension. The European Society of Hypertension (ESH) guidelines suggest that a value of 20% above the stage 2 hypertension limit may indicate a critical point for severe hypertensive crisis in children (1). According to the guidelines published by the American Academy of Paediatrics (AAP), clinicians should be concerned about the development of target organ damage when a child's BP increases 30 mmHg or more above the 95th percentile for age and height (2, 3).
Depending on the degree of BP increase and the presence of acute end-organ damage, a hypertensive crisis can be further classified as a hypertensive emergency or urgency (4). A hypertensive emergency is a life-threatening condition associated with severe BP elevation and organ damage, such as neurological, renal or cardiac dysfunction (5–7). Children can manifest headache, confusions, seizures, nausea or vomiting, visual symptoms and facial palsy (8–10). On the other hand, a hypertensive urgency is defined as a sudden severe hypertension without organ damage and it does not represent a life-threatening condition (5, 11–13).
Most children who experience hypertensive crises have secondary hypertension, most commonly due to kidney disease (14–18). In a study conducted at Great Ormond Street Hospital, the most common cause of severe hypertension was chronic kidney disease including reflux nephropathy, glomerular disease, renovascular disease, obstructive uropathy and haemolytic-uremic syndrome, which together accounted for 76% of the cases (8). In a more recent study on children with severe hypertension, etiologies included kidney transplantation complications, multiorgan failure, renovascular disease and acute renal failure (19–21). Thus, patients who present with acute severe hypertension should be expediently evaluated for secondary causes (2, 22).
Treatment
Hypertensive crises are not common in children, however they represent an emergency that must be promptly treated to prevent irreversible damage of vital organs, including possible neurological and visual sequelae (3, 23, 24).
The ESH guidelines specify that patients presenting a hypertensive emergency should always be treated with intravenous drugs, preferentially administered in continuous infusion and not by bolus, to reduce the risk of hypoperfusion (1). According to the AAP guidelines, however, treatment should be started with enteral drugs if the patient is able to tolerate oral therapy and if life-threatening complications have not yet developed. In fact, intravenous agents should only be used when oral administration is not possible due to the patient's clinical status or when a serious complication has already developed (2).
Both AAP and ESH groups agree that BP should be reduced by no more than 25% of the desired target reduction in the first 8 h; complete normalization of blood pressure should be completed in the subsequent 12–24 h (1, 2).
Sodium nitroprusside appears to be the most widely used first-line agent for hypertensive crises. However, its relative contraindication in children with renal or hepatic disease and its risk to cause cyanide toxicity with prolonged use are a cause for concern (25–27).
There is a lack of robust evidence to guide the evaluation and management of children with acute presentations of severe hypertension. Most of the available data derives from studies conducted in adults; acute severe hypertension infrequently affects pediatric patients and, consequently, data on the efficacy and safety of the majority of antihypertensive agents, as well as the associated adverse events, are very limited in this population.
This review aims to analyse the recent evidence on the pharmacological treatment of pediatric hypertensive crisis; in particular the goal is to identify the drug with the best efficacy and safety profile for the first-line treatment of hypertensive emergencies and urgencies.
Methods
We conducted a review on Medline (https://pubmed.ncbi.nlm.nih.gov) and Cochrane Library selecting studies about the efficacy and safety profile of pharmacological treatments of hypertensive urgencies and emergencies from January 2017 to September 2021.
We used the keywords “hypertension” AND “treatment” AND (“emergency” OR “urgency”) to identify the studies. All potentially relevant titles and abstracts were retrieved and assessed for eligibility by seven investigators independently. We excluded studies based on design (case report, review and systematic review, meta-analysis, animal models or editorials), or patient populations (patient > 18 years). We included randomized controlled trials or observational studies, both prospective and retrospective, with more than ten eligible patients.
Our study conforms to the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines (28).
The full text of each of the selected articles was manually reviewed by three investigators (N.B.P, L.D.M., and R.S.) who were not blinded to the journal name, institution or study authors.
Results
The search retrieved a total of 1,686 references from Medline and 779 from Cochrane Library. After screening the titles and abstracts, we identified 29 studies for full-text review. Following a full-text review we identified a total of five eligible studies meeting our inclusion criteria (5, 25, 29–31) (Figure 1). The selected studies are reported in Table 1. All studies had a retrospective design and were conducted between 2008 and 2019. The study setting was the pediatric intensive care unit (PICU) in four of the five studies (Saqua, Lad, Wu, Stone).
Figure 1. Flow chart: identification of studies via Pubmed and Cochrane Library.
Table 1. Studies meeting inclusion criteria and their characteristics.
Overall, the five eligible studies included a total of 212 children (median 38 patients per study, range 13–68).
All the studies were monocentric and included patients with age range 0–18 years old.
The patients included in the studies suffered from hypertensive emergency and urgency (Saquan, Lim), hypertension crisis (Lad, Wu) and postoperative hypertension (Stone).
Primary outcome of all studies was to evaluate the efficacy of the antihypertensive therapy.
The cause of hypertensive crisis was identified in 212 patients. Main causes were cardiac surgery (32%), chronic kidney disease (28.7%) and patients undergoing mechanical circulatory support (17.9%). Less common causes were tumors (2.8%), pheochromocytoma (2.3%), aortic coarctation (0.9%) and iatrogenic hypertension (0.9% cases). Only four cases presented a hypertensive crisis in the course of essential hypertension (1.8%). In 18 patients (8.4%), the cause was not identified (Saquan) (Liam) (Lad).
Investigated antihypertensive drugs included beta blockers (labetalol, metoprolol, propranolol), calcium channel blockers (nifedipine), ACE-inhibitors (enalapril), diuretics (furosemide) and nitroglycerin (Saquan) (Liam) (Lad). A comparison between two classes of medications (labetalol and nitroglycerin) was performed only in Lad's study.
Both oral and intravenous antihypertensive drugs were analyzed in Lim et al. (29); other studies considered only intravenous administration (5, 25, 29–31).
In Lad et al. work, 56 pediatric intensive care unit (PICU) patients were divided into labetalol and not-labetalol treatment groups. The first included 23 children receiving labetalol infusion as first-line or add-on treatment or transition from other IV antihypertensive infusions (sodium nitroprusside, nitroglycerine) in the first 24 h of management. Non-labetalol group included 33 children who received sodium nitroprusside and/or nitroglycerine infusion for BP control. BP reduction was significantly higher in the labetalol group (62 vs. 30.3% of non-labetalol group, p = 0.03). In addition, the rate of neurological recovery at discharge was significantly higher in the labetalol group (56.6 vs. 18.7% of non-labetalol group, p = 0.02) (25).
Saqan and Thiabat considered 13 patients who underwent metoprolol infusion in PICU. The starting dose was 0.5 mcg/kg/min and was increased according to each patient's BP to a maximum dose of 5 mcg/kg/min. The percentage of systolic BP reduction after 24 h ranged between 15 and 44% of the initial value. All patients were discharged with a BP within the 90th percentile for their age and height. Twelve patients had no neurological sequelae. In this study metoprolol was effective in lowering BP safely, regardless of the etiology of hypertension (5).
Lim et al. analyzed 37 patients who were treated for hypertensive crises in a tertiary pediatric hospital from 2009 to 2015. The choice for initial therapy was between oral nifedipine, oral propranolol, oral enalapril, intravenous labetalol and intravenous furosemide. Oral nifedipine was the most commonly used antihypertensive medication for the initial management of our patients with hypertensive crisis (59.5%). The most frequently administered intravenous drug was labetalol (21.6%). Intravenous furosemide was the first choice for all patients with hypertensive crisis secondary to post-streptococcal glomerulonephritis. No significant statistical differences were found between hypertensive urgency and emergency treatment groups in terms of efficacy. The study concludes that oral nifedipine and intravenous labetalol are both effective treatments (29).
Stone et al. enrolled 68 children undergoing cardiac surgery at the University of Virginia from 2010 to 2015, who received nicardipine for the management of postoperative hypertension. None of the patients discontinued treatment because of adverse effects, required additional antihypertensive agents or transitioned to an alternative antihypertensive drug to achieve the target postoperative blood pressure (31).
Wu et al. reviewed a cohort of 38 patients in mechanical circulatory support (MCS) who received a total of 45 clevidipine infusions. The median age of the patients was 2.7 years and included neonates. Clevedipine was administered as first choice in 57.8% of cases. Twenty-six clevidipine infusions were administered as a single agent without sodium nitroprusside. Seven patients were switched from sodium nitroprusside to clevidipine to avoid cyanide toxicity and a majority of them had elevated serum creatinine. Eleven patients transitioned from clevidipine to enteral antihypertensive agents at PICU discharge (30).
Regarding the safety of the analyzed drugs, the most frequently described adverse effects overall were hypotension and hyperkalemia (25, 31).
In particular, Lad et al. observed hypotension in 13% of patients treated with labetalol and in 15% of patients treated with con nitroglycerin or nitroprusside. Nitroprusside was also associated to hyperkaliemia in 0.03% of patients (25). Patients treated with nicardipine infusion presented hypotension in 13% of cases (31). Clevidipine infusion brought an increase of triglycerides in 9% of patient (30). No side effects were described in Sequan's and Lim's studies.
Discussion
Our review provides updated results on the pharmacological standard of care for pediatric emergency arterial hypertension.
Early treatment of hypertension crises prevents the development of complications in adulthood, such as cardiovascular diseases and organ damage.
Currently, there is no agreement on which drug is the most effective and safe to use as a first line in a hypertensive crisis. According to the European ESH guidelines, sodium nitroprusside and labetalol are the most commonly used drugs for hypertensive emergencies in children (1, 32). The AAP guidelines indicate as possible pharmacological agents esmolol, hydralazine, labetalol, nicardipine and nitroprusside for patients with life-threatening symptoms; while they point to clonidine, fenoldopam, hydralazine, isradipine and minoxidil as pharmacological agents for patients with less severe symptoms (2, 33).
Although not listed among the drugs recommended by the most recent guidelines, oral nifedipine was routinely used for the treatment of hypertensive emergencies, and administered in 50% of patients, in the retrospective study by Lim et al. (29). Oral nifedipine has been associated with an increased risk of renal, cerebral or coronary ischaemia in the adult population and is no longer considered acceptable for the initial treatment of hypertensive crisis (34). However, it has been and is still widely prescribed by pediatricians for the treatment of acute hypertension in children due to the efficacy in blood pressure control and its safety profile (34–36). The pediatric population may be better able to tolerate nifedipine as children typically do not have significant vascular and cardiovascular risk factors, unlike the adult population, which result in significant mortality and morbidity from large changes in end organ perfusion (35, 37).
Beta blockers appear effective and safe according to the recent studies reviewed. Lad et al. (25) showed that labetalol was more effective in BP reduction compared to nitroprusside, chosen as standard of treatment, with similar incidence of side effects. This is the first study comparing the efficacy of the two drugs and it demonstrates a superiority of labetalol over nitroprusside, despite the strong limitations due to the small cohort size and the retrospective nature.
Accordingly, labetalol was the most utilized intravenous drug for the management of hypertensive crises among the analyzed group in the study by Lim et al. (29) and was deemed effective.
Metoprolol appeared safe and effective in the small pediatric cohort admitted to PICU for hypertensive crises reported by Saqan and Thiabat (5).
Interestingly, labetalol treatment was associated with a better neurological outcome than nitroprusside in the study by Lad et al. (25) and Saqan and Thiabat (5) reported that 92% of patients treated with metoprolol had no neurological sequelae.
A good neurological outcome can be the determining factor in the choice of antihypertensive therapy in terms of efficacy and patient management.
In this context, a main role is given by selective calcium-channel blockers. Among these drugs, the use of clevidipine is particularly interesting (30, 38).
The study by Wu et al. on patients admitted to the PICU in mechanical circulatory support, showed how the use of a clevidipine infusion was effective in the management of hypertension and not associated with hypotensive events even in neonatal populations. The use of clevidipine may be reasonable for BP management in pediatric patients on MCS, particularly those with kidney injury at risk of cyanide toxicity with SNP. Moreover, clevidipine is emulsified in fat and provides additional calories without a clear effect on serum triglyceride. Clevidipine is thought to be safe in this population because its effect is limited to peripheral calcium channels without involving central calcium channels and so preserving the myocardial function (30).
Stone et al. analyzed the efficacy of nicardipine, a selective calcium channel blocker, in the PICU management of hypertension after surgery, in particular in patients undergoing cardiac surgery, showing its safety and efficacy (31).
Therefore, we suggest beta blockers or calcium-channel blockers to be used as the first pharmacological line in case of hypertensive crisis, given the demonstrated efficacy and safety. In our review, no main side effects have been reported in the included studies. These drugs should in fact be preferred to the more commonly used sodium nitroprusside (5, 29).
Indeed, there are no recent studies regarding the safety of sodium nitroprusside in the pediatric hypertensive emergency. Sodium nitroprusside, a short-acting intravenous vasodilator, has been utilized for a long time, despite only limited available data on its safety and efficacy. Although this limited body of evidence supports its efficacy in reducing BP, this drug should be used with caution, especially in children whose hypertensive crises are commonly secondary to renal disease, because of the accumulation of its toxic metabolites (cyanide and thiocyanate) (5, 39, 40).
Given the risk of nitric oxide toxicity, in literature new drugs are emerging for the use also in the intensive setting in pediatric patients.
Children who present with hypertensive crises frequently suffer from secondary hypertension, and kidney disease is the most common etiology. In our review the main cause of hypertension crises was cardiac surgery (32%), while chronic kidney disease was only the second most frequent cause (28.7%), differently to the literature. However, our results may be biased by the small pool of studies included and the short period considered (7).
In our review, none of the included studies compared oral and intravenous administration of antihypertensive drugs in terms of efficacy and safety. Furthermore, most studies analyzed the efficacy and safety of single antihypertensive drugs. Only Lad et al. (25) performed a comparison between labetalol and sodium nitroprusside, with the limitations of a retrospective study. There are no randomized controlled trials in the literature comparing the use of different antihypertensive drugs in hypertensive crises in children.
The results of our review must be interpreted in the context of its limitations. First, we limited our search to two main databases (PubMed and Cochrane Library). Secondly, unpublished studies and unreported data were not included. Finally, systematic review was not performed.
Conclusions
The management of pediatric hypertensive emergencies is still an important issue for clinicians, because there is a lack of consensus in literature on the best therapeutic choice.
Beta-blockers seem to be safe and effective in hypertensive crises, more than sodium nitroprusside, although limited data are available. Indeed, calcium-channel blockers seem to be effective and safe, in particular the use of clevidipine during the neonatal age, although limited studies are available. However, further studies should be warranted to define a univocal approach to pediatric hypertensive emergencies.
Author Contributions
NB, RS, LD, MS, BG, AS, and EZ performed the literature review and drafted the initial manuscript. NB, RS, LD, MN, and DM supervised the literature review, provided critical insight, and prepared the final version of the manuscript. All authors contributed to the article and approved the submitted version.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Lurbe E, Agabiti-Rosei E, Cruickshank JK, Dominiczak A, Erdine S, Hirth A, et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens. (2016) 34:1887–920. doi: 10.1097/HJH.0000000000001039
2. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. (2017) 140:e20171904. doi: 10.1542/peds.2017-1904
3. Wu HP, Yang WC, Wu YK, Zhao LL, Chen CY, Fu YC. Clinical significance of blood pressure ratios in hypertensive crisis in children. Arch Dis Child. (2012) 97:200–5. doi: 10.1136/archdischild-2011-300373
5. Saqan R, Thiabat H. Evaluation of the safety and efficacy of metoprolol infusion for children and adolescents with hypertensive crises: a retrospective case series. Pediatr Nephrol. (2017) 32:2107–13. doi: 10.1007/s00467-017-3720-6
6. Flynn JT, Tullus K. Severe hypertension in children and adolescents: pathophysiology and treatment. Pediatr Nephrol. (2009) 24:1101–12. doi: 10.1007/s00467-008-1000-1
7. Patel HP, Mitsnefes M. Advances in the pathogenesis and management of hypertensive crisis. Curr Opin Pediatr. (2005) 17:210–4. doi: 10.1097/01.mop.0000150769.38484.b3
8. Deal JE, Barratt TM, Dillon MJ. Management of hypertensive emergencies. Arch Dis Child. (1992) 67:1089–92. doi: 10.1136/adc.67.9.1089
9. Jorg R, Milani GP, Simonetti GD, Bianchetti MG, Simonetti BG. Peripheral facial nerve palsy in severe systemic hypertension: a systematic review. Am J Hypertens. (2013) 26:351–6. doi: 10.1093/ajh/hps045
10. Ahn CH, Han SA, Kong YH, Kim SJ. Clinical characteristics of hypertensive encephalopathy in pediatric patients. Korean J Pediatr. (2017). 60:266. doi: 10.3345/kjp.2017.60.8.266
11. Chandar J, Zilleruelo G. Hypertensive crisis in children. Pediatr Nephrol. (2012) 27:741–51. doi: 10.1007/s00467-011-1964-0
12. Singh D, Akingbola O, Yosypiv I, El-Dahr S. Emergency management of hypertension in children. Int J Nephrol. (2012) 2012:1–15. doi: 10.1155/2012/420247
13. Aggarwal M, Khan IA. Hypertensive crisis: hypertensive emergencies and urgencies. Cardiol Clin. (2006) 24:135–46. doi: 10.1016/j.ccl.2005.09.002
14. Gupta-Malhotra M, Banker A, Shete S, Hashmi SS, Tyson JE, Barratt MS, et al. Essential hypertension vs. secondary hypertension among children. Am J Hypertens. (2015) 28:73–80. doi: 10.1093/ajh/hpu083
15. Adelman RD, Coppo R, Dillon MJ. The emergency management of severe hypertension. Pediatr Nephrol. (2000) 14:422–7. doi: 10.1007/s004670050787
16. Baracco R, Mattoo TK. Pediatric hypertensive emergencies. Curr Hypertens Rep. (2014) 16:456. doi: 10.1007/s11906-014-0456-6
17. Lee GH, Lee IR, Park SJ, Kim JH, Oh JY, Il Shin J. Hypertensive crisis in children: an experience in a single tertiary care center in Korea. Clin Hypertens. (2016) 22:10. doi: 10.1186/s40885-016-0040-2
18. Ferguson M, Stein D. Evaluation and treatment of hypertensive crises in children. Integr Blood Press Control. (2016) 9:49–58. doi: 10.2147/IBPC.S50640
19. Flynn JT, Mottes TA, Brophy PD, Kershaw DB, Smoyer WE, Bunchman TE. Intravenous nicardipine for treatment of severe hypertension in children. J Pediatr. (2001) 139:38–3. doi: 10.1067/mpd.2001.114030
20. Lingens N, Dobos E, Witte K, Busch C, Lemmer B, Klaus G, et al. Twenty-four-hour ambulatory blood pressure profiles in pediatric patients after renal transplantation. Pediatr Nephrol. (1997) 11:23–6. doi: 10.1007/s004670050226
21. Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens. (2002) 20:2183–89. doi: 10.1097/00004872-200211000-00017
22. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. (1996) 334:13–8. doi: 10.1056/NEJM199601043340103
23. Seeman T, Hamdani G, Mitsnefes M. Hypertensive crisis in children and adolescents. Pediatr Nephrol. (2019) 34:2523–37. doi: 10.1007/s00467-018-4092-2
24. Yang WC, Lin MJ, Chen CY, Wu HP. Clinical overview of hypertensive crisis in children. World J Clin Cases. (2015) 3:510. doi: 10.12998/wjcc.v3.i6.510
25. Lad S, Patil M, Jayashree M, Bansal A, Baranwal A, Nallasamy K, et al. Efficacy and safety of intravenous labetalol in acute hypertensive crisis in children. Indian J Pediatr. (2022) 89:7–12. doi: 10.1007/s12098-021-03707-7
26. Thomas C, Svehla L, Moffett BS. Sodium nitroprusside induced cyanide toxicity in pediatric patients. Expert Opin Drug Saf. (2009) 8:599–602. doi: 10.1517/14740330903081717
27. Moffett BS, Price JF. Evaluation of sodium nitroprusside toxicity in pediatric cardiac surgical patients. Ann Pharmacother. (2008) 42:1600–4. doi: 10.1345/aph.1L192
28. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. (2009) 339:b2700. doi: 10.1136/bmj.b2700
29. Lim AM, Le Chong S, Ng YH, Chan YH, Lee JH. Epidemiology and management of children with hypertensive crisis: a single-center experience. J Pediatr Intens Care. (2020) 9:45–50. doi: 10.1055/s-0039-1698759
30. Wu M, Ryan KR, Rosenthal DN, Jahadi O, Moss J, Kwiatkowski DM. The use of clevidipine for hypertension in pediatric patients receiving mechanical circulatory support. Pediatr Crit Care Med. (2020) 21:e1134–9. doi: 10.1097/PCC.0000000000002562
31. Stone ML, Kelly J, Mistry M, Buck M, Gangemi J, Vergales J. Use of nicardipine after cardiac operations is safe in children regardless of age. Ann Thorac Surg. (2018) 105:181–5. doi: 10.1016/j.athoracsur.2017.05.035
32. Bunchman TE, Lynch RE, Wood EG. Intravenously administered labetalol for treatment of hypertension in children. J Pediatr. (1992) 120:140–4. doi: 10.1016/S0022-3476(05)80619-5
33. Miyashita Y, Peterson D, Rees JM, Flynn JT. Isradipine for treatment of acute hypertension in hospitalized children and adolescents. J Clin Hypertens. (2010) 12:850–5. doi: 10.1111/j.1751-7176.2010.00347.x
34. Yiu V, Orrbine E, Rosychuk RJ, MacLaine P, Goodyer P, Girardin C, et al. The safety and use of short-acting nifedipine in hospitalized hypertensive children. Pediatr Nephrol. (2004) 19:644–50. doi: 10.1007/s00467-004-1444-x
35. Egger DW, Deming DD, Hamada N, Sahney S. Evaluation of the safety of short-acting nifedipine in children with hypertension. Pediatr Nephrol. (2002) 17:35–40. doi: 10.1007/s004670200006
36. Rascher W, Bonzel KE, Ruder H, Müller-wiefel DE, Schärer K. Blood pressure and hormonal responses to sublingual nifedipine in acute childhood hypertension. Clin Exp Hypertens Part A Theory Pract. (1986) 8:859–69. doi: 10.3109/10641968609046605
37. Blaszak RT, Savage JA, Ellis EN. The use of short-acting nifedipine in pediatric patients with hypertension. J Pediatr. (2001) 139:34–7. doi: 10.1067/mpd.2001.114699
38. Kako H, Gable A, Martin D, Beebe A, Thung A, Samora W, et al. A prospective, open-label trial of clevidipine for controlled hypotension during posterior spinal fusion. J Pediatr Pharmacol Ther. (2015) 20:54–60. doi: 10.5863/1551-6776-20.1.54
39. Hammer GB, Lewandowski A, Drover DR, Rosen DA, Cohane C, Anand R, et al. Safety and efficacy of sodium nitroprusside during prolonged infusion in pediatric patients. Pediatr Crit Care Med. (2015) 16:397–403. doi: 10.1097/PCC.0000000000000383
Keywords: hypertension, hypertensive crisis, hypertensive emergency, beta-blockers, calcium-channel blockers, children, pediatric
Citation: Bertazza Partigiani N, Spagnol R, Di Michele L, Santini M, Grotto B, Sartori A, Zamperetti E, Nosadini M and Meneghesso D (2022) Management of Hypertensive Crises in Children: A Review of the Recent Literature. Front. Pediatr. 10:880678. doi: 10.3389/fped.2022.880678
Received: 21 February 2022; Accepted: 25 March 2022;
Published: 15 April 2022.
Edited by:
Orkun Tolunay, Ministry of Health, TurkeyReviewed by:
Donald Lee Batisky, Emory University, United StatesSevgin Taner, Ministry of Health, Turkey
Copyright © 2022 Bertazza Partigiani, Spagnol, Di Michele, Santini, Grotto, Sartori, Zamperetti, Nosadini and Meneghesso. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Nicola Bertazza Partigiani, nicola.bertazzapartigiani@aopd.veneto.it